Results of trial of Elecsys sFlt-1/PlGF immunoassay in preeclampsia published in NEJM- Roche

Roche announced that the New England Journal of Medicine has published the results of PROGNOSIS, a clinical study demonstrating the prognostic value of the company’s Elecsys sFlt-1/PlGF immunoassay ratio test in predicting which pregnant women are at highest risk of developing preeclampsia. The PROGNOSIS study has demonstrated that low ratios of the proteins sFlt-1 and PlGF in the blood of women showing the signs and symptoms of preeclampsia can predict the absence of the condition within a period of one week (the rule-out claim).

The data show that an sFlt-1/PlGF ratio of 38 and below can rule out the development of preeclampsia within the next week with a very high confidence level of 99.3%. Identifying women who are unlikely to develop preeclampsia in the short term will save them from the stress of monitoring and the disruption to their home life caused by a stay in hospital.